Targovax announces clinical trial collaboration with Agenus to test TG mutant RAS vaccination in pancreatic cancer
· The trial will be sponsored by The University of Kansas Cancer Center and led by Dr. Anup Kasi, a leading expert in gastrointestinal cancers · Collaboration partner Agenus will provide PD-1 checkpoint inhibitor (CPI) balstilimab and vaccine adjuvant QS-21 STIMULON™ · The trial has been given approval to proceed by the US Food and Drug Administration (FDA), and will be activated on December 15 Oslo, Norway, 15 December 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it